Novartis Venture Fund logo

Novartis Venture Fund

Europe, Basel-Stadt, Switzerland, Basel

Description

Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.

Investor Profile

Novartis Venture Fund has made 257 investments, with 8 in the past 12 months and 26% as lead.

Stage Focus

  • Series A (34%)
  • Series B (30%)
  • Series C (14%)
  • Series Unknown (8%)
  • Series D (7%)
  • Seed (3%)
  • Series E (2%)
  • Post Ipo Equity (2%)
  • Private Equity (1%)

Country Focus

  • United States (64%)
  • Switzerland (12%)
  • United Kingdom (8%)
  • France (2%)
  • The Netherlands (2%)
  • Ireland (2%)
  • Finland (2%)
  • Germany (2%)
  • Spain (2%)
  • Iceland (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
  • Biopharma
  • Life Science
  • Medical Device
  • Health Diagnostics
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Novartis Venture Fund frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 20
Aravis Ventures
Europe, Zurich, Switzerland, Zürich
Co-Investments: 12
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 19
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 14
Novo Ventures
Europe, Hovedstaden, Denmark, Bagsværd
Co-Investments: 13
SR One
North America, Massachusetts, United States, Cambridge
Co-Investments: 15
Astellas Venture Management
North America, California, United States, Menlo Park
Co-Investments: 13
EQT Life Sciences
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 16
Roche Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 18
Lilly Ventures
North America, Indiana, United States, Indianapolis
Co-Investments: 14

Which angels does Novartis Venture Fund often collaborate with?

JB
North America, California, United States, Menlo Park
Shared Deals: 1
WH
North America, California, United States, San Francisco
Shared Deals: 1
CG
Europe, England, United Kingdom, London
Shared Deals: 1
DV
Europe, Basel-Stadt, Switzerland, Basel
Shared Deals: 1
TJ
North America, Massachusetts, United States, Cambridge
Shared Deals: 2
BD
North America, New York, United States, New York
Shared Deals: 1
Shared Deals: 1
SP
Europe, Germany
Shared Deals: 1
FM
North America, United States
Shared Deals: 1
SH
North America, New Hampshire, United States, Center Harbor
Shared Deals: 1

What are some of recent deals done by Novartis Venture Fund?

Atalanta Therapeutics

Boston, Massachusetts, United States

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

BiotechnologyHealth CareLife Science
Series BJan 28, 2025
Amount Raised: $97,000,000
Rhygaze

Basel, Basel-Stadt, Switzerland

Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.

BiotechnologyHealth CareTherapeutics
Series AJan 10, 2025
Amount Raised: $86,000,000
Alesta Therapeutics

Leiden, Zuid-Holland, The Netherlands

Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.

Biotechnology
Series AJan 8, 2025
Amount Raised: $67,301,858
Citryll

Oss, Noord-Brabant, The Netherlands

Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.

BiopharmaBiotechnologyMedicalMedical DeviceNeuroscience
Series BDec 9, 2024
Amount Raised: $89,720,936
LOQUS23 THERAPEUTICS

London, England, United Kingdom

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease.

Biotechnology
Series AOct 2, 2024
Amount Raised: $46,420,022
ONL Therapeutics

Ann Arbor, Michigan, United States

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Series DSep 13, 2024
Amount Raised: $65,000,000
Epsilogen

London, England, United Kingdom

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.

BiopharmaBiotechnologyGeneticsLife ScienceOncologyTherapeutics
Series BSep 9, 2024
Amount Raised: $16,338,566
Exsilio Therapeutics

Boston, Massachusetts, United States

Exsilio develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.

Biotechnology
Series AJun 25, 2024
Amount Raised: $82,000,000
FundaMental Pharma

Heidelberg, Baden-Wurttemberg, Germany

FundaMental Pharma is a neuroscience company with a portfolio at the preclinical stage.

Health Care
SeedApr 11, 2024
Amount Raised: $2,896,048
Capstan Therapeutics

San Diego, California, United States

Capstan Therapeutics is advancing cell engineering to develop therapeutics for a broad range of diseases.

BiotechnologyHealth CareTherapeutics
Series BMar 20, 2024
Amount Raised: $175,000,000